Alnylam Pharmaceuticals (Nasdaq: ALNY) has won European Commission approval for Amvuttra (vutrisiran) to treat transthyretin ...

Alnylam Pharmaceuticals ALNY +1.01% Get Free Report is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish ...

The fact that multiple Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) insiders offloaded a considerable amount of ...

For payers, claims for rare disease treatments used to be uncommon. Not anymore, thanks to an increasing number of new, ...

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is among the best stocks added in a Growth Stock Portfolio.

With CT scans picking up more cases of sclerosing mesenteritis, be prepared to diagnose this poorly understood autoimmune ...

The growing incidence of infectious diseases, cancer, and chronic illnesses has substantially increased the demand for ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

In the last week, the United States market has been flat, yet it is up 10.0% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks ...